<DOC>
	<DOC>NCT00539929</DOC>
	<brief_summary>This is a double-blind, multicenter study to assess the efficacy and safety of E6201 topical administration to pre-identified marker lesions in adult subjects with chronic plaque type psoriasis. Treatment duration is 8 weeks, followed by a 4-week period without treatment. Pharmacokinetic samples will be obtained pre-and post treatment.</brief_summary>
	<brief_title>Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>INCLUSION CRITERIA: Males and females 18 years or older with a clinical diagnosis of mildtomoderate plaquetype psoriasis for â‰¥12 months prior to screening Female participants postmenopausal &gt;1 year or surgically sterile Two representative and similar target lesions for the condition, each of 1525 centimeters squared (cm^2), up to 50 cm^2 in surface area Target lesion severity score of 48 on a scale of 0 to 12, where, in the opinion of the Investigator, 0 equals no evidence of disease and 12 equals severe induration, erythema, scaling, and pruritus Prescription medications, if applicable, for chronic conditions allowed but must be on a stable regimen prior to and during the study; this is also applicable for dietary supplements and overthecounter (OTC) drugs Participants able and willing to give informed consent EXCLUSION CRITERIA Use of any, concomitant, topical treatment for psoriasis, excluding emollients Use of any, concomitant, systemic treatment for psoriasis, including ultraviolet radiation (UVR) light Evidence of significant hepatic, gastrointestinal, renal, respiratory, endocrine, hematological, neurological, psychiatric, musculoskeletal, rheumatologic, or cardiovascular system abnormalities Evidence of any clinically significant deviation from normal with respect to medical history, physical examination, vital signs, 12lead electrocardiogram (ECG), or clinical laboratory determinations. If any participant has an abnormal clinical laboratory test finding that meets specified criteria, that participant will be retested by repeated blood draw and clinical laboratory assessment. If the abnormal test finding is confirmed, the participant will be excluded from the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>